Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Education and Clinical Science, Karolinska Institutet, Stockholm, Sweden; Department of Pediatrics, Sachs' Children's Hospital, South General Hospital, Stockholm, Sweden.
J Allergy Clin Immunol. 2018 Aug;142(2):510-516.e6. doi: 10.1016/j.jaci.2017.09.023. Epub 2017 Dec 5.
Polyunsaturated fatty acids (PUFAs) are hypothesized to modulate the risk of allergic disease. However, evidence from previous studies is inconclusive, and limited longitudinal data exist using circulating biomarkers of PUFA intake and metabolism.
We aimed to investigate associations between n-3 and n-6 PUFAs at age 8 years and asthma, rhinitis, and aeroallergen sensitization at age 16 years.
Proportions of n-3 PUFAs (very long-chain n-3 [VLC n-3; sum of eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid] and α-linolenic acid) and n-6 PUFAs (linoleic acid and arachidonic acid [AA]) in blood samples at age 8 years were measured for 940 children from the prospective Swedish birth cohort BAMSE (Children, Allergy, Milieu, Stockholm, Epidemiology). Allergic disease phenotypes were defined by using questionnaires and IgE measures at the ages of 8 and 16 years. Logistic regression was used to examine potential associations.
A higher proportion of total VLC n-3 PUFAs in plasma at age 8 years was associated with a reduced risk of prevalent asthma, rhinitis, and aeroallergen sensitization at age 16 years and with incidence of asthma between 8 and 16 years (adjusted odds ratio, 0.67; 95% CI, 0.47-0.94). AA was associated with a reduced risk of asthma, aeroallergen sensitization, and allergic rhinitis. The findings were most evident for allergic phenotypes of asthma and rhinitis. Additionally, AA was associated with an increased probability of asthma and rhinitis remission between 8 and 16 years of age.
Higher proportions of certain VLC n-3 and very long-chain n-6 PUFAs in plasma phospholipids at age 8 years were associated with a reduced risk of allergic disease at age 16 years.
多不饱和脂肪酸（PUFAs）被认为可以调节过敏疾病的风险。然而，先前研究的证据并不一致，并且使用循环生物标志物来评估 PUFAs 摄入和代谢的纵向数据有限。
我们旨在研究 8 岁时 n-3 和 n-6 PUFAs 与 16 岁时哮喘、鼻炎和变应原致敏之间的关联。
在前瞻性瑞典出生队列 BAMSE（儿童、过敏、环境、斯德哥尔摩、流行病学）中，对 940 名儿童在 8 岁时的血液样本中 n-3 PUFAs（超长链 n-3 [VLC n-3；二十碳五烯酸、二十二碳五烯酸和二十二碳六烯酸的总和]和α-亚麻酸）和 n-6 PUFAs（亚油酸和花生四烯酸[AA]）的比例进行了测量。在 8 岁和 16 岁时，通过问卷调查和 IgE 测量来确定过敏疾病表型。使用逻辑回归来检查潜在的关联。
8 岁时血浆中总 VLC n-3 PUFAs 比例较高与 16 岁时患哮喘、鼻炎和变应原致敏的风险降低以及 8 至 16 岁之间哮喘的发生率降低相关（调整后的优势比，0.67；95%CI，0.47-0.94）。AA 与哮喘、变应原致敏和过敏性鼻炎的风险降低相关。这些发现对于哮喘和鼻炎的过敏表型最为明显。此外，AA 与 8 至 16 岁之间哮喘和鼻炎缓解的可能性增加相关。
8 岁时血浆磷脂中某些 VLC n-3 和超长链 n-6 PUFAs 比例较高与 16 岁时过敏疾病的风险降低相关。
